499195-60-7|Ethyl 4-(2-chloropyrimidin-4-yl)benzoate| Ambeed

Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

{[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

Quality Control of [ 499195-60-7 ] Purity: 97% SDS Specification

COA

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

NMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

CNMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

HPLC

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

LC-MS

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

1-2 Day Shipping
High Quality
Technical Support

Product Details of [ 499195-60-7 ]

CAS No. :	499195-60-7
Formula :	C₁₃H₁₁ClN₂O₂
M.W :	262.69
SMILES Code :	O=C(OCC)C1=CC=C(C2=NC(Cl)=NC=C2)C=C1
MDL No. :	MFCD09861393
InChI Key :	PTSZMMLYAGLVQJ-UHFFFAOYSA-N
Pubchem ID :	11065261

Safety of [ 499195-60-7 ]

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H302-H315-H319-H335
Precautionary Statements:	P261-P305+P351+P338

Computational Chemistry of [ 499195-60-7 ] Show Less

Physicochemical Properties

Num. heavy atoms	18
Num. arom. heavy atoms	12
Fraction Csp3	0.15
Num. rotatable bonds	4
Num. H-bond acceptors	4.0
Num. H-bond donors	0.0
Molar Refractivity	68.56
TPSA ? Topological Polar Surface Area: Calculated from Ertl P. et al. 2000 J. Med. Chem.	52.08 Å²

Lipophilicity

Log P_o/w (iLOGP)? iLOGP: in-house physics-based method implemented from Daina A et al. 2014 J. Chem. Inf. Model.	2.85
Log P_o/w (XLOGP3)? XLOGP3: Atomistic and knowledge-based method calculated by XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry	3.05
Log P_o/w (WLOGP)? WLOGP: Atomistic method implemented from Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.	2.97
Log P_o/w (MLOGP)? MLOGP: Topological method implemented from Moriguchi I. et al. 1992 Chem. Pharm. Bull. Moriguchi I. et al. 1994 Chem. Pharm. Bull. Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.	1.96
Log P_o/w (SILICOS-IT)? SILICOS-IT: Hybrid fragmental/topological method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	3.31
Consensus Log P_o/w? Consensus Log P_o/w: Average of all five predictions	2.83

Water Solubility

Log S (ESOL):? ESOL: Topological method implemented from Delaney JS. 2004 J. Chem. Inf. Model.	-3.62
Solubility	0.0631 mg/ml ; 0.00024 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble
Log S (Ali)? Ali: Topological method implemented from Ali J. et al. 2012 J. Chem. Inf. Model.	-3.81
Solubility	0.0407 mg/ml ; 0.000155 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble
Log S (SILICOS-IT)? SILICOS-IT: Fragmental method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	-5.27
Solubility	0.00141 mg/ml ; 0.00000538 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Moderately soluble

Pharmacokinetics

GI absorption? Gatrointestinal absorption: according to the white of the BOILED-Egg	High
BBB permeant? BBB permeation: according to the yolk of the BOILED-Egg	Yes
P-gp substrate? P-glycoprotein substrate: SVM model built on 1033 molecules (training set) and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94	No
CYP1A2 inhibitor? Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91	Yes
CYP2C19 inhibitor? Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86 External: ACC=0.80 / AUC=0.87	Yes
CYP2C9 inhibitor? Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set) and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85 External: ACC=0.71 / AUC=0.81	Yes
CYP2D6 inhibitor? Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set) and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87	No
CYP3A4 inhibitor? Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set) and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86	No
Log Kp (skin permeation)? Skin permeation: QSPR model implemented from Potts RO and Guy RH. 1992 Pharm. Res.	-5.74 cm/s

Druglikeness

Lipinski? Lipinski (Pfizer) filter: implemented from Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500 MLOGP ≤ 4.15 N or O ≤ 10 NH or OH ≤ 5	0.0
Ghose? Ghose filter: implemented from Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480 -0.4 ≤ WLOGP ≤ 5.6 40 ≤ MR ≤ 130 20 ≤ atoms ≤ 70	None
Veber? Veber (GSK) filter: implemented from Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10 TPSA ≤ 140	0.0
Egan? Egan (Pharmacia) filter: implemented from Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88 TPSA ≤ 131.6	0.0
Muegge? Muegge (Bayer) filter: implemented from Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600 -2 ≤ XLOGP ≤ 5 TPSA ≤ 150 Num. rings ≤ 7 Num. carbon > 4 Num. heteroatoms > 1 Num. rotatable bonds ≤ 15 H-bond acc. ≤ 10 H-bond don. ≤ 5	0.0
Bioavailability Score? Abbott Bioavailability Score: Probability of F > 10% in rat implemented from Martin YC. 2005 J. Med. Chem.	0.55

Medicinal Chemistry

PAINS? Pan Assay Interference Structures: implemented from Baell JB. & Holloway GA. 2010 J. Med. Chem.	0.0 alert
Brenk? Structural Alert: implemented from Brenk R. et al. 2008 ChemMedChem	0.0 alert: heavy_metal
Leadlikeness? Leadlikeness: implemented from Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350 XLOGP ≤ 3.5 Num. rotatable bonds ≤ 7	No; 1 violation:MW<0.0
Synthetic accessibility? Synthetic accessibility score: from 1 (very easy) to 10 (very difficult) based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties, trained on 12'782'590 molecules and tested on 40 external molecules (r² = 0.94)	2.09

Application In Synthesis of [ 499195-60-7 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Downstream synthetic route of [ 499195-60-7 ]

[ 499195-60-7 ] Synthesis Path-Downstream 1~15

1
[ 68-12-2 ]
4-{1-[(E)-Cyanoimino]-ethyl}-benzoic acid ethyl ester [ No CAS ]
[ 499195-60-7 ]

References: [1]Synthetic Communications,2002,vol. 32,p. 3011 - 3018.

2
[ 38430-55-6 ]
polystyrene-bound benzaldehyde [ No CAS ]
[ 499195-60-7 ]

References: [1]Synthetic Communications,2002,vol. 32,p. 3011 - 3018.

3
[ 3934-20-1 ]
[ 4334-88-7 ]
[ 499195-60-7 ]

Yield	Reaction Conditions	Operation in experiment
60%	With sodium carbonate;tetrakis(triphenylphosphine) palladium(0); In toluene; at 75 - 100℃;	Example 1 - Synthesis of Compound 3; A mixture of 4-ethoxycarbonylphenyl boronic acid (23.11 g, 119 mmol), 2,4- dichloropyrimidine (16.90 g, 113 mmol), toluene (230 mL) and aqueous sodium carbonate (2 M, 56 mL) was stirred vigorously and nitrogen was bubbled through the suspension for 15 minutes. Tetrakis(triphenylphosphine)palladium[0] (2.61 g, 2.26 mmol) was added. Nitrogen was bubbled through for another 10 min., the mixture was heated to 100C, then at 75C overnight. The mixture was cooled, diluted with ethyl acetate (200 mL), water (100 mL) was added and the layers were separated. The aqueous layer was extracted with ethyl acetate (100 ml) and the two organic extracts were combined. The organics were washed with brine, filtered through sodium sulfate, <n="58"/>concentrated, and the resultant solid was triturated with methanol (100 niL) and filtered. The solids were washed with methanol (2 x 30 mL) and air dried. This material was dissolved in acetonitrile (150 mL) and dichloromethane (200 mL), stirred with MP.TMT Pd-scavenging resin (Agronaut part number 800471) (7.5 g) over 2 days. The solution was filtered, the solids were washed with dichloromethane (2 x 100 mL), and the filtrate concentrated to give ethyl 4-(2-chloropyrimidin-4-yl)benzoate as anoff-white solid (17.73 g, 60%) - additional washing with dichloromethane yielded a further 1.38 g and 0.5 g of product. 1H NMR (300 MHz, J6-DMSO) delta 8.89 (IH, d, J= 5.0 Hz); 8.32 (2H, d, J= 8.7 Hz); 8.22 (IH, d, J= 5.5 Hz); 8.12 (2H, d, J= 8.7 Hz); 4.35 (2H, q, J= 7.1 Hz); 1.34 (3H, t, J= 7.1 Hz); LC-ESI-MS (method B): rt 7.3 min.; m/z 263.0 / 265.0 [M+H]+.
37%		Ester 1 : Preparation of Ethyl 4-(2-chloropyrimidin-4-yl)benzoate. To a solution of 2,4-dichloropyrimidine [70 g, 470 mmol] in DMF [600 mL] was added (PPh3)2PdCl2 [9.9 g, 14 mmol] and mixture was heated to 90C for 1 h. To this, (4-(ethoxycarbonyl)phenyl)boronic acid [91 g, 470 mmol] was added and mixture was heated to 90C for additional 0.5 h. A solution of potassium bicarbonate [282 g, 2.8 mol] in 200 mL of water was added to reaction mixture and stirred for 0.5 h at 90C. After completion of reaction, mixture was quanched in ice cooled water [500 mL]. The off white solid obtained was filtered, washed with water and dried under vacuum to get title compound. [45 g, 37%].

References: [1]Patent: WO2008/109943,2008,A1 .Location in patent: Page/Page column 56-57.
[2]Patent: WO2015/19365,2015,A1 .Location in patent: Page/Page column 17; 18.

4
[ 2524-67-6 ]
[ 499195-60-7 ]
[ 1056634-62-8 ]

Yield	Reaction Conditions	Operation in experiment
88%	With toluene-4-sulfonic acid; In 1,4-dioxane;Heating / reflux;	A mixture of <strong>[499195-60-7]ethyl 4-(2-chloropyrimidin-4-yl)benzoate</strong> (26.15 g, 99.7 mmol) and 4-morpholinoaniline (23.10 g, 129.6 mmol) was suspended in 1,4-dioxane (250 mL). p- Toluenesulfonic acid monohydrate (17.07 g, 89.73 mmol) was added. The mixture was heated at reflux for 40 h., cooled to ambient temperature, concentrated then the residue was partitioned between ethyl acetate and 1 : 1 saturated sodium bicarbonate/water (IL total). The organic phase was washed with water (2 x 100 mL) and concentrated. The aqueous phase was extracted with dichloromethane (3 x 200 mL). The material which precipitated during this workup was collected by filtration and set aside. The liquid organics were combined, concentrated, triturated with methanol (200 mL) and filtered to yield additional yellow solid. The solids were combined, suspended in methanol (500 mL), allowed to stand overnight then sonicated and filtered. The solids were washed with methanol (2x 50 mL) to give, after drying, ethyl 4-(2-(4- morphonlinophenylamino)pyrimidin-4-yl)benzoate (35.39 g , 88%). 1H NMR (300 MHz, J6-DMSO) delta 9.49 (IH, s); 8.54 (IH, d, J= 5.0 Hz); 8.27 (2H, d, J= 8.7 Hz); 8.10 (2H, d, J= 8.7 Hz), 7.66 (2H, d, J= 9.1 Hz); 7.38 (IH, d, J= 5.0Hz); 6.93 (2H, d, J= 8.7 Hz); 4.35 (2H, q, J= 6.9 Hz), 3.73 (4H, m); 3.04 (4H, m); 1.34 (3H, t, J= 6.9 Hz); LC-ESI- MS (method B): rt 7.5 min.; m/z 404.1 [M+H]+.

References: [1]Patent: WO2008/109943,2008,A1 .Location in patent: Page/Page column 57.

5
[ 499195-60-7 ]
4-(2-((4-(4-(2-oxopyrrolidin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)benzoic acid [ No CAS ]

References: [1]Patent: WO2015/19365,2015,A1 .

6
[ 499195-60-7 ]
N-(cyanomethyl)-4-(2-((4-(4-(2-oxopyrrolidin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)benzamide [ No CAS ]

References: [1]Patent: WO2015/19365,2015,A1 .

7
1-(1-(4-aminophenyl)piperidin-4-yl)pyrrolidin-2-one [ No CAS ]
[ 499195-60-7 ]
ethyl 4-(2-((4-(4-(2-oxopyrrolidin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)benzoate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
82%	With trifluoroacetic acid; In isopropyl alcohol; at 120℃; for 16h;Sealed tube;	Step 1 : Preperation of ethyl 4-(2-((4-(4-(2-oxopyrrolidin-l-yl)piperidin-l-yl) phenyl) amino) pyrimidin-4-yl)benzoate. To a solution of <strong>[499195-60-7]ethyl 4-(2-chloropyrimidin-4-yl)benzoate</strong> (7.09 g, 27.0 mmol), in isopropyl alcohol [100 mL] was added l-(l-(4-aminophenyl)piperidin-4- yl)pyrrolidin-2-one (7.0 g, 27.0 mmol). To this, trifluoro acetic acid (4.62 g, 40.0 mmol) was added and mixture was heated at 120 C in sealed tube for 16 h. After completion of reaction, mixture was quenched in water, basified with ammonia solution and extracted with ethyl acetate. Organic layer was washed with water, dried over sodium sulfate and removed under reduced pressure to give crude off white solid compound. Purification of crude product was done by the way of column chromatography (Si02, hexane to 30 % EtOAc in hexane) to get solid compound (10.7 g, 82%). The title compound was characterized by spectral analysis. ESI-MS: 486.2 (M+H)+.

References: [1]Patent: WO2015/19365,2015,A1 .Location in patent: Page/Page column 25.

8
4-(4-(6-oxa-3-azabicyclo[3.1.1]heptan-3-yl)piperidin-1-yl)aniline [ No CAS ]
[ 499195-60-7 ]
ethyl 4-(2-((4-(4-(6-oxa-3-azabicyclo[3.1.1]heptan-3-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)benzoate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With bis-triphenylphosphine-palladium(II) chloride; caesium carbonate; 2,2'-bis-(diphenylphosphino)-1,1'-binaphthyl; In N,N-dimethyl acetamide; at 25 - 90℃; for 16h;Inert atmosphere;	Step I : Preparation of ethyl 4-(2-((4-(4-(6-oxa-3-azabicyclo[3.1.1]heptan-3- yl)piperidin- 1 -yl)phenyl)amino)pyrimidin-4-yl)benzoate. Placed <strong>[499195-60-7]ethyl 4-(2-chloropyrimidin-4-yl)benzoate</strong> [4.37 g, 16.64 mmol] in rb flask followed by DMA [60 mL]. To this, 4-(4-(6-oxa-3-azabicyclo[3.1.1]heptan-3- yl)piperidin-l-yl)aniline (Amine 17) [3.5 g, 12.80 mmol], cesium carbonate [6.26 g, 19.20 mmol], BINAP [1.19 g, 1.92 mmol] and bis triphenyl phosphie Pd (Il)dichloride [1.34 g, 1.92 mmol] was added at 25C under N2 atm. The mixture was heated to 90C for 16 h. After completion of reaction mixture was quanched in water, compound was extracted with ethyl acetate (50 mL X 4), Combined the organic layers and washed with water and brine soln. The organic layer was dried over Na2S04, filtered and concentrated under reduced pressure to afford desired product as light yellow solid. Title compound was characterised by spectral analysis. ESI-MS : 500.30 (M+H)+.

References: [1]Patent: WO2015/19365,2015,A1 .Location in patent: Page/Page column 34.

9
[ 499195-60-7 ]
[ 945749-71-3 ]